Daiichi, Eisai Look Beyond Japan To Expanded Markets In Southeast Asia (Japan)
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo and Eisai are reaching beyond their Japan bases into other Asian markets to seek faster growth than they are seeing at home. Daiichi is looking to India as a good market for some of its flagship products, beginning in the spring, and is hiring a 100-person sales force, but Taiwan and other Asian markets also are in Daiichi plans. Eisai plans drug trials in China where it hopes to tap into a huge market, beginning with one for hepatitis B. Also in Eisai plans are member countries of the Association of Southeast Asian Nations where Eisai is looking for a 20 percent annual sales increase. (Click here for more - may require a subscription
You may also be interested in...
Japanese Pharma Majors Expanding Into India
NEW DELHI - Faced with margin pressures elsewhere, pharmaceutical multinationals have been eyeing the burgeoning Indian market ever since the country signed the Trade-Related Aspects of Intellectual Property Rights pact. Initially hesitant, Japanese pharma companies are now following in the footsteps of Western companies, using India as a hub for low-cost contract manufacturing and clinical trials
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.